The Penn Orthopaedics Sarcoma Program
is devoted to the management of patients with benign and malignant tumors of bone and soft tissues. The Program’s mission is to build a world-class multidisciplinary clinical team complemented by a strong foundation of basic and translational research to better diagnose and treat patients with bone and soft-tissue sarcomas.
The most common primary malignant bone lesions (sarcomas) include osteosarcoma, chondrosarcoma and Ewing sarcoma. Primary bone sarcomas are rare (~1% of all adult cancers) and can occur from infancy through late adulthood. The majority of patients with these tumors have pain at the bony site in addition to swelling or a stiff adjacent joint. Because symptoms can mimic those of many common injuries or conditions, individualized bone cancer management at Penn Medicine begins with a confirmative diagnosis.
A complex process, accurate diagnosis of sarcoma involves imaging studies and an image-guided needle biopsy. These assays are then analyzed by an interdisciplinary team of musculoskeletal radiologists and pathologists, medical/pediatric oncologists, radiation oncologists and surgeons from orthopaedics, neurosurgery, plastics surgery and general surgery. MRI scans with specific tumor sequences allow Penn orthopaedic oncologists to better plan surgical procedures by accurately determining the tumor characteristics and extent of disease.
Once the diagnosis of bone sarcoma has been confirmed, treatment plans are designed. Treatment varies depending on tumor type and stage, location, patient age, and adjuvant or neoadjuvant medical treatments. The objectives of treatment include prevention of disease recurrence, progression or metastasis and preservation of limb function. Limb preservation techniques for malignant tumors of bone and soft tissue are a specialty of the Penn Orthopaedics Sarcoma Program.
Surgical management of bone sarcoma at Penn has benefited from advances in the technology of internal fixation, soft tissue attachments to prostheses, and biologic options to recreate living bone. Metal prosthetic joints have become the most common method of reconstruction for patients when bone sarcoma is near a joint. Improvements in biomechanics, metallurgy and engineering have allowed for the development of advanced, modular prostheses that provide a more durable, long-lasting reconstruction for patients who are candidates for limb salvage surgery.
Future advances in the treatment of patients with osteosarcoma will come from the laboratory in the form of new drugs or biologic agents that can specifically target the tumor cells to prevent metastasis.
RK, an 18-year-old, began experiencing pain in his right hip in June of 2014. The pain gradually worsened, requiring increasing doses of pain medication. Imaging studies at an outside institution initially suggested a benign synovial condition called pigmented villonodular synovitis (PVNS). With the development of worsening symptoms and a limp, repeat imaging studies were ordered, and these showed a destructive bone-producing lesion in the proximal femur with a surrounding soft tissue mass (Figs. 1 and 2).
RK was referred to the Penn Orthopaedic Oncology service and had a CT-guided needle biopsy of the right proximal femur lesion that revealed a high-grade osteosarcoma. Staging studies showed no evidence of metastasis. Subsequently, he began systemic chemotherapy and was scheduled for resection of the primary tumor.
Because his osteosarcoma was located in the proximal femur and extended into the hip joint, RK's surgical options included a hindquarter amputation or an extraarticular wide resection and complex hip/acetabular reconstruction. He opted for limb salvage, and a team of hip reconstruction and orthopaedic oncology surgeons was assembled.
A successful extraarticular resection of the right hip joint and proximal femur was performed with negative margins and 70% necrosis of the tumor as a result of chemotherapy. Reconstruction involved a proximal femoral megaprosthesis with reconstruction of the abductor and iliopsoas tendons and a complex acetabular reconstruction with a tantalum uncemented component and multiple augments (Fig. 3).
After surgery, RK was in a hip abduction brace for 6 weeks and protected weight bearing for three months to allow bony ingrowth into the tantalum acetabular component. Having completed chemotherapy, he remains cancer free, and is now walking with a cane and working to regain right leg strength in physical therapy. RK continues to be monitored carefully for metastasis or recurrence. He is walking normally, has good strength of the leg and is attending college with a goal to become a physician someday.
Perelman Center for Advanced Medicine
West Pavilion, 4th Floor
3400 Civic Center Boulevard
Philadelphia, PA 19104
Garfield Duncan Building,
301 South 8th Street
Philadelphia, PA 19106
Published on: September 13, 2017
Mirabello L, Troisi RJ, Savage SA. Osteosarcoma incidence and survival rates from 1973 to 2004: Data from the Surveillance, Epidemiology, and End Results Program. Cancer 2009;115:1531-1543.
About the Penn Orthopaedics Sarcoma Program
The Sarcoma Program at Penn Medicine has one of the few medical teams in the world devoted to bone and soft-tissue sarcomas. We use the most advanced technology and treatments to pinpoint the type of cancer and spare limbs. As part of a National Cancer Institute comprehensive care center, the Penn Sarcoma Program meets strict standards for cancer care and research - and as such, is considered a leader in the field.
Our team approach to treatment means specialists in several areas collaborate in the care of each patient and create a personalized plan to provide the most successful outcome, while focusing on quality of life.
Penn Faculty Team
Chief, Orthopaedic Oncology
Director of the Sarcoma Program, Abramson Cancer Center
Professor, Vice-Chair of Faculty Affairs, Department of Orthopaedic Surgery
Chair, Department of Orthopaedic Surgery
Chair, Pathology, Pennsylvania Hospital
Director for Pathology and Laboratory Medicine at Pennsylvania Hospital
Director, GI-CREP Program
Chief, Section of Radiation Oncology, Pennsylvania Hospital
Medical Director, CyberKnife
Medical Director, Penn Radiation Oncology Network
Co-Director, Translational Spine Research Lab
Director, Neurosurgery Quality Improvement Initiative
Vice Chairman for Operations, Department of Neurosurgery
Residency Program Diector, Director of Neurotrauma
Director, Abramson Cancer Center
Director, Bone or Soft Tissue Sarcoma Program